Prevalence and Contributing Factors of Hypothyroidism in Hematological Malignancy Patients Compared to Healthy Individuals: A Systematic Review and Meta-Analysis - Summary - MDSpire
Advertisement
Prevalence and Contributing Factors of Hypothyroidism in Hematological Malignancy Patients Compared to Healthy Individuals: A Systematic Review and Meta-Analysis
To evaluate the incidence of hypothyroidism among patients with hematological malignancies (HMs) and identify specific factors contributing to its development.
Key Findings:
Higher incidence of hypothyroidism in HM patients compared to healthy individuals, indicating a need for targeted monitoring.
Risk factors include type of malignancy, gender, and specific treatments received, which may inform clinical practices.
Chemotherapy and radiotherapy significantly increase the risk of developing hypothyroidism, necessitating further investigation.
Interpretation:
The findings highlight the need for careful monitoring of thyroid function in HM patients, especially those undergoing specific treatments.
Limitations:
Variability in study designs and methodologies may affect the reliability of results, potentially skewing the overall findings.
Limited access to full texts of some studies may have restricted data inclusion, impacting the comprehensiveness of the review.
Conclusion:
Identifying the incidence and risk factors for hypothyroidism in HM patients can enhance clinical management and improve patient outcomes, aligning with the study's objective.
One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.
